NCI (NCIT) Earns News Sentiment Rating of 0.36

News headlines about NCI (NASDAQ:NCIT) have been trending positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NCI earned a news sentiment score of 0.36 on Accern’s scale. Accern also assigned press coverage about the information technology services provider an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.

Insider Buying and Selling by Quarter for NCI (NASDAQ:NCIT)

Shares of NCI (NASDAQ NCIT) traded up 0.852% during mid-day trading on Friday, reaching $20.725. The company had a trading volume of 5,649 shares. NCI has a 1-year low of $10.98 and a 1-year high of $21.00. The firm has a 50-day moving average price of $18.39 and a 200-day moving average price of $15.07. The stock has a market capitalization of $280.84 million, a price-to-earnings ratio of 46.365 and a beta of 0.98.

NCI (NASDAQ:NCIT) last posted its earnings results on Tuesday, May 9th. The information technology services provider reported $0.25 EPS for the quarter, topping the consensus estimate of $0.21 by $0.04. The firm had revenue of $78.75 million for the quarter, compared to analyst estimates of $76.55 million. NCI had a negative return on equity of 2.86% and a negative net margin of 1.02%. Equities analysts expect that NCI will post $1.01 earnings per share for the current year.

A number of research analysts have commented on the stock. Cowen and Company set a $24.00 price target on shares of NCI and gave the company a “buy” rating in a research report on Thursday, June 8th. ValuEngine raised NCI from a “hold” rating to a “buy” rating in a research note on Friday, June 2nd. FBR & Co reissued a “hold” rating and set a $11.00 price objective on shares of NCI in a research note on Tuesday, April 4th. Noble Financial reissued a “buy” rating on shares of NCI in a research note on Wednesday, June 14th. Finally, Zacks Investment Research lowered NCI from a “hold” rating to a “sell” rating in a research note on Saturday, April 8th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $17.50.

ILLEGAL ACTIVITY WARNING: “NCI (NCIT) Earns News Sentiment Rating of 0.36” was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/nci-ncit-given-daily-coverage-optimism-score-of-0-36-updated/1020009.html.

About NCI

NCI, Inc is a provider of enterprise services and solutions to defense, intelligence, healthcare and civilian government agencies. The Company provides information technology (IT), and professional services and solutions by leveraging its core service offerings, which include cloud computing and IT infrastructure optimization; cybersecurity and information assurance; engineering and logistics support; enterprise information management and advanced analytics; health IT and medical support; IT service management; modeling, simulation, and training, and agile development and integration.

Receive News & Ratings for NCI Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NCI Inc and related companies with our FREE daily email newsletter.

 


Latest News

Hitters in Major League Baseball on Record Home Run Pace
Hitters in Major League Baseball on Record Home Run Pace
Atlanta Considering Playing Freddie Freeman at Third
Atlanta Considering Playing Freddie Freeman at Third
Injury to Gleyber Torres Adds to Questions About Yankees
Injury to Gleyber Torres Adds to Questions About Yankees
Game Winning Home Run Completes Nolan Arenado Cycle
Game Winning Home Run Completes Nolan Arenado Cycle
New York Yankees and Masahiro Tanaka Hit Hard Again
New York Yankees and Masahiro Tanaka Hit Hard Again
Victor Martinez Diagnosed with Irregular Heartbeat
Victor Martinez Diagnosed with Irregular Heartbeat


Leave a Reply

 
© 2006-2017 BBNS.